Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HY 0001a

Next Previous
Drug Profile

HY 0001a

Alternative Names: HY-0001; HY-0001a

Latest Information Update: 19 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sichuan Huiyu Pharmaceutical
  • Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Preclinical Cancer

Most Recent Events

  • 09 Mar 2026 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT07069062)
  • 02 Dec 2025 Sichuan Huiyu Pharmaceutical withdraws prior to enrolment the phase I/II trial for Solid tumours (Late-stage diseases, Metastatic-diseases) in China (IV) due to a strategic amendment to the protocol (NCT07069062)
  • 07 Jul 2025 Sichuan Huiyu Pharmaceutical plans a phase I/II trial for Solid tumours (Late-stage diseases, Metastatic-diseases, Second-line or greater therapy) in China in July 2025 (IV) (NCT07069062)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top